| Chapter title |
Molecular Basis and Targeted Inhibition of CBFβ-SMMHC Acute Myeloid Leukemia
|
|---|---|
| Chapter number | 15 |
| Book title |
RUNX Proteins in Development and Cancer
|
| Published in |
Advances in experimental medicine and biology, March 2017
|
| DOI | 10.1007/978-981-10-3233-2_15 |
| Pubmed ID | |
| Book ISBNs |
978-9-81-103231-8, 978-9-81-103233-2
|
| Authors |
Lucio H. Castilla, John H. Bushweller |
| Editors |
Yoram Groner, Yoshiaki Ito, Paul Liu, James C. Neil, Nancy A. Speck, Andre van Wijnen |
| Abstract |
Acute myeloid leukemia (AML) is characterized by recurrent chromosomal rearrangements that encode for fusion proteins which drive leukemia initiation and maintenance. The inv(16) (p13q22) rearrangement is a founding mutation and the associated CBFβ-SMMHC fusion protein is essential for the survival of inv(16) AML cells. This Chapter will discuss our understanding of the function of this fusion protein in disrupting hematopoietic homeostasis and creating pre-leukemic blasts, in its cooperation with other co-occurring mutations during leukemia initiation, and in leukemia maintenance. In addition, this chapter will discuss the current approaches used for the treatment of inv(16) AML and the recent development of AI-10-49, a selective targeted inhibitor of CBFβ-SMMHC/RUNX1 binding, the first candidate targeted therapy for inv(16) AML. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 10 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 3 | 30% |
| Unspecified | 2 | 20% |
| Student > Master | 2 | 20% |
| Researcher | 1 | 10% |
| Student > Ph. D. Student | 1 | 10% |
| Other | 0 | 0% |
| Unknown | 1 | 10% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 30% |
| Unspecified | 2 | 20% |
| Agricultural and Biological Sciences | 2 | 20% |
| Biochemistry, Genetics and Molecular Biology | 1 | 10% |
| Engineering | 1 | 10% |
| Other | 0 | 0% |
| Unknown | 1 | 10% |